FDA generic approvals hit a new record, but the effort's not paying off yet

Under former commissioner Scott Gottlieb, the FDA pledged to approve more low-cost generics to compete with pricey branded meds. And that it did in fiscal 2019, signing off on a whopping 1,171 of them—a new record. But new research found the approvals haven't necessarily delivered the hoped-for savings.